Background
Metastasis is an important step in the development of tumors and causes poor prognosis [
1]. Epithelial–mesenchymal transition (EMT), as a major actor modulating tumor metastasis [
2,
3], may be involved in the interaction between the tumor cells and tumor microenvironment (TME) [
2,
4]. EMT-programmed tumor cells could secrete amounts of inflammatory mediators to change cellular and non-cellular components in TME [
5‐
8]. As the most abundant immune cells in TME, tumor-associated macrophages (TAMs) can respond to various factors produced by tumor cells in the TME [
9,
10]. EMT-programmed tumor cells can secrete mediators to activate TAMs to M2 phenotype [
10], thereby facilitating tumor progression and metastasis [
11‐
14]. Although the interplay between tumor cells and macrophages has been established, the understanding of EMT tumor cells modulating TAM polarization is limited.
Multiple signaling pathways cooperate in the initiation and progression of EMT [
15]. Recent studies have showed that the Notch pathway was involved in tumor EMT [
16‐
20]. NOTCH2, as one of the NOTCH receptors, is a single-pass transmembrane receptor activated by ligands of the DSL (Delta-like and Jagged) family in humans. Ligand binding to the extracellular domain of NOTCH2 induces release of the NOTCH2 intracellular domain (N2ICD; activated NOTCH2). Then N2ICD translocates to the nucleus, where it binds the transcription factor RBPJ, resulting in the complex activation of target genes related to EMT [
18]. In addition, the Notch pathway activation was necessary in GATA3-induced IL-4 secretion [
21,
22], which was widely accepted to activate M2-like macrophages [
23]. It indicated that the Notch pathway plays pivotal roles in tumor EMT and macrophage alternative polarization in TME. However, whether the NOTCH pathway promotes CRC EMT to affect TAM polarization is still incompletely understood.
MicroRNAs (miRNAs) are a large class of small non-coding RNAs, which regulated the expression of mRNAs by binding the 3′-untranslated regions (3′-UTRs) or amino acid coding sequences [
9]. miR-195-5p as a member of the miR-15/107 family has been widely explored in various cancers and was considered as a tumor suppressor to inhibit proliferation [
24] and enhance radiochemosensitivity [
25,
26] in CRC [
12]. We had demonstrated that miR-195-5p is a suppressor of YAP1 in colorectal cancer EMT. However, how miR-195-5p-mediated EMT modulates cytokine secretion in CRC to affect TAM polarization is unclear. Taking into account that NOTCH2 may be a target of mR-195-5p, we hypothesized that miR-195-5p/NOTCH2 may influence CRC EMT status and modulate IL-4 mediated M2-like TAM polarization.
In this study, we performed an integrated analysis with nine datasets and identified miR-195-5p deregulation in primary tumors compared to paired adjacent normal tissue (ANT). A high level of miR-195-5p in patients was with favorable survival. In vitro and in vivo experiments have showed that aberrant expression of miR-195-5p could significantly reduce proliferation, migration, invasion, and EMT, confirming its anti-tumor functions. We further revealed that miR-195-5p inhibited NOTCH2 expression in a post-transcriptional manner, leading to downregulation of GATA3 and IL-4, ultimately suppressing M2-like TAM polarization. These observations highlighted the role of miR-195-5p/NOTCH2-mediated CRC EMT in TAM alternative polarization.
Materials and methods
Detailed materials and methods are provided in supplemental experimental procedures (Additional file
1).
Patient samples
For this study, we collected 30 paired CRC samples and ANT (distance to cancer > 5 cm) from patients who had been diagnosed with primary CRC by pathological assessment of tissues and undergone surgeries with complete prognostic information at the Zhongnan Hospital of Wuhan University between January 2016 and July 2018. No any neoadjuvant radiotherapy or/and chemotherapy was managed. The study was endorsed by the Research Ethics Committee of Wuhan University (Wuhan, Hubei, PR China). Informed consents were obtained from all participating patients.
Cell lines
The normal intestinal epithelium cell line NCM460 and CRC cell lines (DLD-1, HCT116, SW480, SW620, HCT116, and HT29) were obtained from the Cell Bank of Wuhan University. The monocyte cell line was purchased from ATCC. Cells were cultured in RPMI 1640 medium (Invitrogen, Shanghai, China) containing 10% heat-inactivated (56 °C, 30 min) fetal calf serum, streptomycin (100 U/mL), and penicillin (100 U/mL), and maintained in a humidified atmosphere of 5% CO2 at 37 °C.
Transfection of miR-195 mimic, inhibitor, and siRNA of the target gene
Hsa-miR-195 mimic and mimic negative control (NC), hsa-miR-195 inhibitor, and inhibitor negative control (NC) were purchased from RiboBio (Guangzhou, China). NOTCH2 siRNAs (Notch2-homo-1815, 2501 and 3130) were purchased from GenePharma (Shanghai, China). Cells were cultured in complete medium at least 24 h before transfection. Cells were washed with phosphate-buffered saline (PBS, pH 7.4) before transient transfection. Transfections were performed by Lipofectamine 2000 (Invitrogen, USA) according to the manufacturer’s protocol with RNA oligonucleotides at a final concentration of 50 nM.
RNA immunoprecipitation (RIP) assay
RIP was performed using the Magna RIP RNA-Binding Protein Immunoprecipitation Kit (Millipore, MA, USA) according to the manufacturer’s protocol. In short, 5 × 107 cells were lysed in polysome lysis buffer for each group. The expression of AGO2 protein was detected by western blotting, and then the supernatant was immunoprecipitated with antibody to AGO2 with protein A/G magnetic beads at 4 °C overnight. Magnetic bead-bound complexes with AGO2 were immobilized, and unbound material was washed off six times; after digesting proteins with Proteinase-K, the RNAs were extracted for quantitative real-time PCR and AGE (agarose gel electrophoresis) analyses.
Xenograft assays
Ten BALB/c athymic nude mice (female, 4–6 weeks old and 16–20 g) were purchased from Hubei Research Center of Laboratory Animals (Wuhan, China). All animal experiments were carried out in accordance with the Guide for the Care and Use of Laboratory Animals of Wuhan University. Each mouse was subcutaneously injected with 5 × 10
6 HCT116 cells on the right flank region. And the liposomal clodronate was injected intravenously for macrophage depletion [
27]. After 8 days, the transplanted nude mice were randomly divided into two groups (
n = 5 each), miR-195-5p agomir or miR agomir NC (RiboBio, Guangzhou, China) was directly injected into the implanted tumor at the dose of 2 nmol/50 μL PBS, and THP1-induced macrophages were injected into the caudal veins at the dose of 10
6 cells/50 μL per mouse every 3 days for eight times. Tumor dimension was measured at indicative time points. After 29 days, the weights and volumes of tumors were analyzed. One milliliter of blood was gathered via cardiac puncture into EDTA-containing tubes per mouse. The xenograft tumor and blood were collected for further experiments.
CTC capture
The mice blood samples were processed within 24 h of collection. Circulating tumor cells (CTCs) were isolated and identified by CTCBIOPSY® (Wuhan YZY Medical Science and Technology Co., Ltd., Wuhan, China) as previously reported by our group [
28]. In brief, 1 mL blood was diluted with the 0.9% sodium chloride solution into 5-mL total volumes, then transferred to CTCBIOPSY® tubes with an 8-μm diameter aperture membrane. The samples were filtered by positive pressure from 12 to 20 mmHg through the device tubes. After that, the membranes in the device tubes were stained with Wright’s stain, then the morphology and number were rechecked using an ordinary microscope (BX51-Olympus, Japan).
Statistical analysis
For comparisons, one-way analyses of variance, Fisher’s exact tests, chi-squared tests, and two-tailed Student’s t tests were performed, as appropriate. P < 0.05 was considered statistically significant. The results were expressed as the mean ± SD from at least three independent experiments. Kaplan–Meier curves were used to calculate overall survivals, and the differences were analyzed by a log-rank test. All statistical analyses were conducted using the SPSS 20.0 statistical software (SPSS Inc., IL, USA).
Discussion
In this study, we found that tumor cells undergoing EMT could secrete IL-4 to activate macrophages to a M2-like phenotype, and dysregulation of miR-195-5p mediated EMT status of CRC cells by regulating NOTCH2. miR-195-5p is a vital role in CRC EMT-related TAM alternative activation and is associated with good prognosis in colorectal tumor patients.
Integrated analysis has been used to identify differentially expressed genes at the mRNA and miRNA in tumors. We had found the downregulation of miR-195-5p in CRC by analyzing seven studies which included 376 paired samples before [
29]. However, the more qualified studies included, the higher the reliability of the results will be. So we further assessed the role of miR-195-5p in CRC by incorporating two new studies with 677 paired samples. Above all, reduced expression of miR-195-5p in primary CRC was correlated with poor overall survivals, suggesting that miR-195-5p can be an effective diagnostic and prognostic marker in the clinical setting. Secondly, altered expression of miR-195-5p in colon cancer cell lines considerably modulated cell growth, migration, and invasion. Thirdly, miR-195-5p directly regulated expression of NOTCH2 in a post-transcriptional manner by targeting its 3′-UTR. Finally, miR-195-5p/NOTCH2 modulated IL-4 secretion in CRC to affect M2-like TAM polarization.
miR-195-5p is a member of evolutionarily conserved miRNAs termed the miR-15/107 family which has been suggested to have considerable potential in prognostic prediction [
33‐
35]. miR-195-5p acts as a tumor suppressor in tumor progression by targeting numerous genes, such as YAP1 in CRC [
29], RPS6KB1 in prostate cancer [
35], MMP14 in cervical carcinoma [
36], and NOTCH2 in osteosarcoma [
12]. So the rescue experiment is needed to investigate the role of miR-195-5p in the NOTCH2 pathway. Importantly, we showed that after NOTCH2 knockdown in CRC cells, the inhibiting effects of miR-195-5p on EMT progression and cell invasion were partially abrogated. Thus, we propose that downregulation of miR-195-5p in CRC enhanced EMT by deregulating NOTCH2. Similarly, Jin and colleagues also found that miR-195-5p could overcome CRC stemness and chemoresistance by inhibiting NOTCH2 and RBPJ [
26]. So miR-195-5p/NOTCH2 may play a crucial role in CRC EMT and progression.
Recent studies have showed that the Notch pathway was involved in tumor EMT [
16,
18‐
20,
37]. The overexpression of NOTCH2 has been observed in numerous human cancer types, such as non-small cell lung cancer [
19], gastric carcinoma [
20], and CRC [
38]. Maraver et al. had revealed that the Notch pathway affected the process of epithelial–mesenchymal transition through its effector HES1 targeting Vimentin promoter in bladder cancer [
18]. Intriguingly, they also found the overexpression of ZEB2 after the Notch was inhibited or HES1 was downregulated, even though HES1 did not bind to the ZEB2 promoter observably. Moreover, our previous study also revealed that ZEB2 is downregulated after miR-195-5p upregulation [
29]. However, ZEB2 is not a predicted target of miR-195-5p or YAP1, so there may be another regulation between miR-195-5p and ZEB2. Inspired by Maraver’s work, our finding of miR-195-5p/NOTCH2-mediated CRC EMT may be partly contributed by ZEB2. Further investigation is needed to elucidate regulation of NOTCH2 to ZEB2 in CRC EMT.
On the other hand, the NOTCH2 pathway is necessary for IL-4 production [
22,
39]. Peng had found that NOTCH2 mediated the initiation of Th2 cytokines (such as IL-4 and IL-5) in Th2 cells through GATA3 [
21]. Zhu and colleague proved that GATA3 was required for in the initiation of Il4 transcription during Th2 cell differentiation with a conditional knockout of a Gata3 mouse model [
40]. And Tanaka further confirmed that DNase I–hypersensitive site 2 (HS2) element situated in the second intron of the IL-4 locus as a critical enhancer was strictly controlled by GATA-3 binding [
22]. Their work had preliminarily illustrated the role of NOTCH2/GATA3 in IL-4 production in Th2 cells. However, the mechanism of IL-4 secretion in CRC is still unclear. In this work, we show that NOTCH2 induced tumor cell EMT status, resulting in the secretion of IL-4 to promote M2 polarization of TAMs. Additionally, after silencing NOTCH2, the expressions of GATA3 and IL-4 were decreased, whereas inhibited IL-4 production by the inhibitor did not decrease levels of NOTCH2 and GATA3. These might indicate that there is a NOtCH2/GATA3/IL-4 axis in CRC cells to affect TAM polarization.
TAMs have been widely recognized as a favorable condition for tumor progression, including tumor cell growth, EMT, and immune suppression in TME. In TME, TAMs were mixed with the M1/M2 phenotype, which may play opposite roles in CRC progression [
41‐
43]. Numerous studies tended to M2-like (CD163
high CD80
low IL-10
high TGF-β
high) TAMs, which were closely related to poor prognosis of CRC [
44]. In this study, THP1-induced macrophages became CRC-conditioned TAMs after incubation with transfected colon tumor cells or cell supernatant. The resultant TAMs displayed characteristics of M2-like macrophages, with CD163
high, CD80
low, IL-10
high, TGF-β
high, and IL-10
high phenotypes. Conversely, after silencing NOTCH2 and inhibiting IL-4, TAMs seemed to be an M1-like phenotype (CD163
low, CD80
high, and TGF-β
low). In TME, M2-like TAMs, which infiltrate into the tumor invasive front, secreted multiple cytokines such as IL-10, TGF-β, and IL-13, to suppress the immune reaction, stimulate angiogenesis and EMT, and remodel ECM [
10]. The crucial role of M2-like TAMs in CRC EMT has been preliminarily determined. Reversely, our data showed that EMT-programmed tumor cells produced high levels of IL-4, sequentially causing the increase of M2-like TAM recruitment and polarization in vitro and in vivo. Silenced NOTCH2 and inhibited IL-4 could reduce M2-like TAMs. So these results demonstrated that different tumor cells’ EMT status could affect IL-4-related M2-like TAM polarization. Numerous studies focused on the role of TAMs in tumor progression [
11,
41,
43,
45], and rare studies are concerned about tumor EMT status affecting TAM polarization [
4,
14]. Our results firstly indicated that miR-195-5p/NOTCH2 regulated IL-4 expression while modulating the EMT of tumor cells, thereby promoting TAM polarizations. It is likely to become a new therapeutic target in CRC.